Dr. Christopher G. Meyer is a rheumatologist in Asheville,North Carolina. He graduated from University of Arizona College of Medicine in 2003 and has been in practice for 19 years.
Male
1598984155
Description | # of Times Performed | # of Patients | Average Charge ($) |
---|---|---|---|
Aspiration and/or injection of large joint or joint capsule | 28.0 | 18.0 | 193.5 |
Insertion of needle into vein for collection of blood sample | 787.0 | 339.0 | 10.0 |
X-ray of lower and sacral spine, 2 or 3 views | 13.0 | 13.0 | 109.0 |
X-ray of hand, 2 views | 61.0 | 31.0 | 184.59016393 |
X-ray of knee, 1 or 2 views | 21.0 | 11.0 | 177.14285714 |
X-ray of foot, 2 views | 33.0 | 17.0 | 112.33333333 |
Bone density measurement using dedicated X-ray machine | 73.0 | 73.0 | 250.0 |
Blood test, comprehensive group of blood chemicals | 13.0 | 12.0 | 41.0 |
Blood test, lipids (cholesterol and triglycerides) | 15.0 | 11.0 | 54.0 |
Liver function blood test panel | 838.0 | 295.0 | 35.0 |
Manual urinalysis test with examination using microscope | 24.0 | 20.0 | 27.0 |
Vitamin D-3 level | 159.0 | 131.0 | 94.0 |
Calcium level | 145.0 | 95.0 | 26.0 |
Creatine kinase (cardiac enzyme) level | 31.0 | 21.0 | 30.0 |
Blood creatinine level | 915.0 | 350.0 | 20.0 |
Creatinine level to test for kidney function or muscle injury | 23.0 | 20.0 | 22.0 |
Cyanocobalamin (vitamin B-12) level | 22.0 | 21.0 | 67.0 |
Ferritin (blood protein) level | 26.0 | 18.0 | 57.0 |
Folic acid level | 16.0 | 16.0 | 45.0 |
Iron level | 21.0 | 20.0 | 24.0 |
Iron binding capacity | 21.0 | 20.0 | 27.0 |
Parathormone (parathyroid hormone) level | 24.0 | 21.0 | 99.0 |
Blood test, thyroid stimulating hormone (TSH) | 26.0 | 23.0 | 52.0 |
Uric acid level, blood | 32.0 | 20.0 | 20.0 |
Complete blood cell count (red cells, white blood cell, platelets), automated test | 903.0 | 325.0 | 43.0 |
Red blood cell sedimentation rate, to detect inflammation | 897.0 | 331.0 | 30.0 |
Measurement C-reactive protein for detection of infection or inflammation | 871.0 | 323.0 | 35.0 |
Measurement of complement (immune system proteins) | 54.0 | 17.0 | 52.0 |
Measurement of antibody for rheumatoid arthritis assessment | 31.0 | 31.0 | 73.0 |
Measurement of DNA antibody | 19.0 | 18.0 | 40.0 |
Measurement of antibody for assessment of autoimmune disorder | 96.0 | 15.0 | 58.0 |
Rheumatoid factor analysis | 30.0 | 29.0 | 54.0 |
Tuberculosis test | 83.0 | 81.0 | 150.0 |
Hepatitis B core antibody (IgM) measurement | 12.0 | 11.0 | 35.0 |
Hepatitis C antibody measurement | 12.0 | 11.0 | 43.0 |
Detection test for Hepatitis B surface antigen | 12.0 | 11.0 | 27.0 |
Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 19.0 | 19.0 | 137.0 |
Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 130.0 | 57.0 | 36.0 |
Infusion of chemotherapy into a vein up to 1 hour | 533.0 | 117.0 | 257.09193246 |
Infusion of chemotherapy into a vein | 108.0 | 29.0 | 84.0 |
New patient office or other outpatient visit, typically 30 minutes | 15.0 | 15.0 | 278.0 |
New patient office or other outpatient visit, typically 45 minutes | 23.0 | 23.0 | 319.0 |
Established patient office or other outpatient visit, typically 15 minutes | 586.0 | 349.0 | 140.0 |
Established patient office or other outpatient, visit typically 25 minutes | 449.0 | 260.0 | 206.0 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17475.0 | 40.0 | 75.0 |
Injection, denosumab, 1 mg | 4020.0 | 47.0 | 40.0 |
Injection, golimumab, 1 mg, for intravenous use | 16572.0 | 28.0 | 30.48 |
Injection, infliximab, excludes biosimilar, 10 mg | 4523.0 | 19.0 | 110.0 |
Injection, tocilizumab, 1 mg | 47480.0 | 20.0 | 11.0 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 107.0 | 23.0 | 5.0 |
Injection, zoledronic acid, 1 mg | 95.0 | 19.0 | 200.0 |
Infusion, normal saline solution, 250 cc | 116.0 | 31.0 | 28.0 |
Cookies on this website are used to improve your experience and display advertising. You agree to the use of cookies by continuing to use this website. Our Privacy Policy contains more information about how we use cookies.